Cannabis oil fails to ease Parkinson’s pain in trial
Cannabis-Based Oil for Pain and Other Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial.
AI Summary
A 9-week randomized, placebo-controlled phase II trial tested an oral Cannabis sativa oil in people with Parkinson’s disease who had chronic pain. The formulation contained CBD and THC, with a final daily dose of 43.88 mg CBD and 0.96 mg THC. The study enrolled 101 participants, of whom 87 completed it.
Compared with placebo, the cannabis oil did not significantly improve Parkinson’s-related pain or other non-motor symptoms. The study also reported no serious adverse events, but its main conclusion was that this particular CBD/THC formulation did not provide a measurable benefit for pain or other non-motor symptoms in people with Parkinson’s disease. These results do not establish whether different doses, formulations, or treatment periods might have different effects.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.